WO2000007571A3 - Formulierungen mit probiotisch wirksamen mikroorganismen - Google Patents

Formulierungen mit probiotisch wirksamen mikroorganismen Download PDF

Info

Publication number
WO2000007571A3
WO2000007571A3 PCT/AT1999/000192 AT9900192W WO0007571A3 WO 2000007571 A3 WO2000007571 A3 WO 2000007571A3 AT 9900192 W AT9900192 W AT 9900192W WO 0007571 A3 WO0007571 A3 WO 0007571A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
active microorganisms
microorganisms
probiotically active
probiotically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AT1999/000192
Other languages
English (en)
French (fr)
Other versions
WO2000007571A2 (de
Inventor
Helmut Viernstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP99938048A priority Critical patent/EP1102580A2/de
Priority to AU52704/99A priority patent/AU5270499A/en
Publication of WO2000007571A2 publication Critical patent/WO2000007571A2/de
Publication of WO2000007571A3 publication Critical patent/WO2000007571A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Beschrieben wird eine Formulierung, die stabilisierte Mikroorganismen und Puffersubstanzen enhält, welche den Mikroorganismen nach dem Dispergieren und der Aufnahme in den Verdauungstrakt, die Passage durch den Magen bei Erhalt der Lebensfähigkeit ermöglicht.
PCT/AT1999/000192 1998-08-06 1999-07-29 Formulierungen mit probiotisch wirksamen mikroorganismen Ceased WO2000007571A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP99938048A EP1102580A2 (de) 1998-08-06 1999-07-29 Formulierungen mit probiotisch wirksamen mikroorganismen
AU52704/99A AU5270499A (en) 1998-08-06 1999-07-29 Formulations having probiotically active microorganisms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0136098A AT407008B (de) 1998-08-06 1998-08-06 Formulierungen mit probiotisch wirksamen mikroorganismen
ATA1360/98 1998-08-06

Publications (2)

Publication Number Publication Date
WO2000007571A2 WO2000007571A2 (de) 2000-02-17
WO2000007571A3 true WO2000007571A3 (de) 2000-05-11

Family

ID=3512210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT1999/000192 Ceased WO2000007571A2 (de) 1998-08-06 1999-07-29 Formulierungen mit probiotisch wirksamen mikroorganismen

Country Status (4)

Country Link
EP (1) EP1102580A2 (de)
AT (1) AT407008B (de)
AU (1) AU5270499A (de)
WO (1) WO2000007571A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
AU2001272369A1 (en) * 2000-07-17 2002-01-30 Chr. Hansen A/S Methods and formultations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1287745A1 (de) 2001-08-24 2003-03-05 The Procter & Gamble Company Kaubare Zusammmensetzung mit Probiotika
DE102006054260A1 (de) * 2006-02-28 2007-09-27 Lohmann Animal Health Gmbh & Co. Kg Wasser stabilisierende Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung
US20110223251A1 (en) * 2008-08-28 2011-09-15 Chr-Hansen A/S Bacterial composition
BRPI1008011A2 (pt) 2009-02-23 2015-08-25 Chr Hansen As Processo para fabricação de composição de bactérias de ácido lático
FR2963239B1 (fr) * 2010-08-02 2013-03-08 Vetalis Formes galeniques effervescentes solides pour animaux
PH12013500224A1 (en) 2010-08-04 2013-04-08 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
TR201007613A2 (tr) * 2010-09-16 2012-04-24 Yed�Tepe �N�Vers�Tes� Liyofilize biyopestisit efervesan granül ve üretim yöntemi
MX2013010343A (es) 2011-03-09 2014-04-30 Univ Minnesota Composicion y metodos para el transplante de microbiota de colon.
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
CN103550401B (zh) * 2013-11-19 2016-06-22 浙江美保龙生物技术有限公司 一种复合微生态制剂泡腾片的制备方法
WO2015154140A1 (en) * 2014-04-09 2015-10-15 Kambouris Shares Pty Ltd Methods and compositions for delivering a probiotic
CA2985827A1 (en) 2015-05-14 2016-11-17 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
AU2016268158B2 (en) 2015-05-22 2022-03-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
CN110831606A (zh) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
WO2019032573A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061894A (en) * 1963-03-01 1967-03-15 Lucien Nouvel Therapeutically active bacterial preparations
EP0393909A1 (de) * 1989-04-13 1990-10-24 Beecham Group p.l.c. Zusammensetzung
WO1994018997A1 (en) * 1993-02-24 1994-09-01 Valio Ltd. Method of enhancing immune response to oral vaccines
WO1997016198A1 (de) * 1995-11-02 1997-05-09 Chr. Hansen Biosystems A/S Probiotisch wirksame formulierung
US5785990A (en) * 1995-07-10 1998-07-28 Merrick's, Inc. Feed fortifier and enhancer for preruminant calves and method of using same
FR2770778A1 (fr) * 1997-11-12 1999-05-14 Investigations Therapeutiques Composition pour le traitement des gastro-enterites aigues, procede de fabrication de cette composition et solution de traitement obtenue a partir de cette composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3626M (fr) * 1963-11-13 1965-10-18 Lucien Nouvel Médicament pour affections intestinales.
FI840816A0 (fi) * 1984-03-01 1984-03-01 Farmos Oy Bakteriepreparat
GR861387B (en) * 1985-05-29 1986-10-02 Pioneer Hi Bred Int Method of treating gastrointestinal disease in animals
DE4033996A1 (de) * 1990-10-25 1992-04-30 Karl Heinz Hoelzel Enzymatisches stoffwechselprodukt zur symbioselenkung und verfahren zu seiner herstellung
US5340577A (en) * 1992-07-29 1994-08-23 The United States Of America, As Represented By The Secretary Of Agriculture Probiotic for control of salmonella

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061894A (en) * 1963-03-01 1967-03-15 Lucien Nouvel Therapeutically active bacterial preparations
EP0393909A1 (de) * 1989-04-13 1990-10-24 Beecham Group p.l.c. Zusammensetzung
WO1994018997A1 (en) * 1993-02-24 1994-09-01 Valio Ltd. Method of enhancing immune response to oral vaccines
US5785990A (en) * 1995-07-10 1998-07-28 Merrick's, Inc. Feed fortifier and enhancer for preruminant calves and method of using same
WO1997016198A1 (de) * 1995-11-02 1997-05-09 Chr. Hansen Biosystems A/S Probiotisch wirksame formulierung
FR2770778A1 (fr) * 1997-11-12 1999-05-14 Investigations Therapeutiques Composition pour le traitement des gastro-enterites aigues, procede de fabrication de cette composition et solution de traitement obtenue a partir de cette composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GIROLA M ET AL: "Efficacy of probiotic preparation with living, freeze-dried lactic acid bacteria and yeast on child diarrhoea", ARCHIVIO DI MEDICINA INTERNA, 1995, pages 62 - 72, XP002035135 *

Also Published As

Publication number Publication date
AT407008B (de) 2000-11-27
EP1102580A2 (de) 2001-05-30
WO2000007571A2 (de) 2000-02-17
ATA136098A (de) 2000-04-15
AU5270499A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
WO2000007571A3 (de) Formulierungen mit probiotisch wirksamen mikroorganismen
AU2001279202A1 (en) Compositions containing phosphate and xanthan gum variants
AU2001252513A1 (en) Composition exhibiting enhanced formulation stability and delivery of tropical active ingredients
AU1232600A (en) Dosage forms containing taste masked active agents
WO2001041785A3 (en) Enzyme treatment for infection
EP1642506A3 (de) verwendung von äurestabilen subtilisinproteasen in tierfutter
AU2487699A (en) Alteration of amino acid compositions in seeds
AU2002243005A1 (en) Vital cell preparations containing lactic acid bacterium as the active ingredient and lactic acid bacterium-containing foods
WO2002056712A3 (en) Highly acidic metalated organic acid as a food additive
AU2002342907A1 (en) Gel capsules containing active ingredients and use thereof
HUP9701437A3 (en) Use of complex lipides as stabilizing additives in pharmaceutical compositions containing digestive enzymes, pharmaceutical compns. and kits
AU2001235737A1 (en) Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
FR2827774B1 (fr) Preparations pharmaceutiques et/ou dietetiques contenant un extrait vegetal titre en composes actifs et des micro-organismes probiotiques
WO2001098235A3 (de) 3,4-dihydroxybenzyl-substituierte kohlensäurederivate und ihre verwendung als antioxidantien
WO2000074712A3 (en) Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
MY140870A (en) Nutrition supplement containing lactobacillus acidophilus, yeast and soy protein
AU6213699A (en) Nutritional and pharmaceutical compositions
AU2001275144A1 (en) Compositions for enhancing therapeutic effects containing herbals and/or nutritional supplements and/or minerals and/or vitamins
AU2001238589A1 (en) Edible product with live and active probiotics
WO2003088765A3 (de) Funktionsnahrungsmittel enthaltend eine phospholipid-haltige stabile matrix
AU2511997A (en) Composition containing milnacipran and idazoxan for use as combined pharmaceutical preparation
AU2003246566A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
AU2001252741A1 (en) Pharmaceutical composition containing itraconazole with gastric ph-independentlyimproved solubility and preparation method thereof
AU2001230543A1 (en) Physiologically active compositions based upon active ingredients of basidiomycotina and araliaceae
AU2001295501A1 (en) Foodstuff and animal feedstuff supplement compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999938048

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999938048

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999938048

Country of ref document: EP